Ladenburg Thalmann Financial Services’s Teva Pharmaceuticals TEVA Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$693K	Buy	70,813 +5,579	+9%	+$49.8K	﹤0.01%	1553
2019 Q3	$449K	Sell	65,234 -13,443	-17%	-$103K	﹤0.01%	1848
2019 Q2	$726K	Sell	78,677 -9,405	-11%	-$113K	0.01%	1452
2019 Q1	$1.38M	Sell	88,082 -1,646	-2%	-$29K	0.01%	973
2018 Q4	$1.39M	Sell	89,728 -11,609	-11%	-$238K	0.01%	860
2018 Q3	$2.18M	Buy	101,337 +27,631	+37%	+$641K	0.02%	684
2018 Q2	$1.26M	Hold	73,706	–	–	0.01%	929
2018 Q1	$1.26M	Sell	73,706 -10,068	-12%	-$197K	0.01%	929
2017 Q4	$1.59M	Buy	83,774 +7,694	+10%	+$116K	0.02%	807
2017 Q3	$1.35M	Sell	76,080 -4,471	-6%	-$101K	0.01%	819
2017 Q2	$2.67M	Buy	80,551 +4,543	+6%	+$141K	0.03%	480
2017 Q1	$2.44M	Buy	76,008 +25,634	+51%	+$875K	0.03%	493
2016 Q4	$1.85M	Buy	50,374 +15,304	+44%	+$611K	0.03%	545
2016 Q3	$1.61M	Buy	35,070 +2,731	+8%	+$142K	0.02%	573
2016 Q2	$1.62M	Buy	32,339 +4,016	+14%	+$214K	0.03%	548
2016 Q1	$1.52M	Sell	28,323 -2,438	-8%	-$143K	0.03%	522
2015 Q4	$2.02M	Buy	30,761 +1,674	+6%	+$103K	0.04%	412
2015 Q3	$1.65M	Sell	29,087 -8,415	-22%	-$546K	0.03%	447
2015 Q2	$2.22M	Sell	37,502 -1,367	-4%	-$84.3K	0.04%	397
2015 Q1	$2.42M	Buy	38,869 +11,330	+41%	+$659K	0.05%	372
2014 Q4	$1.58M	Sell	27,539 -166	-0.6%	-$9.25K	0.04%	425
2014 Q3	$1.49M	Sell	27,705 -3,975	-13%	-$211K	0.04%	376
2014 Q2	$1.66M	Sell	31,680 -32	-0.1%	-$1.64K	0.05%	342
2014 Q1	$1.68M	Buy	31,712 +8,019	+34%	+$371K	0.05%	304
2013 Q4	$950K	Buy	23,693 +6,008	+34%	+$237K	0.03%	459
2013 Q3	$668K	Sell	17,685 -1,964	-10%	-$76.6K	0.02%	553
2013 Q2	$770K	Buy	+19,649	New	+$765K	0.03%	481

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Ladenburg Thalmann Financial Services's TEVA Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its Teva Pharmaceuticals (TEVA) stake by 8.6% in Q4 2019, buying an estimated $49.8K and bringing the position to 70,813 shares worth $693K. The position accounts for ﹤0.01% of the portfolio, ranked #1553.

Ladenburg Thalmann Financial Services first reported a position in TEVA in Q2 2013 and has held it in 27 quarters since. The position peaked at $2.67M in Q2 2017. 436 funds tracked by Wall St. Rank hold TEVA as of Q4 2019.

Ladenburg Thalmann Financial Services held 70,813 shares of Teva Pharmaceuticals worth $693K as of Q4 2019.
Ladenburg Thalmann Financial Services bought 5,579 Teva Pharmaceuticals shares in Q4 2019, an estimated $49.8K.
Teva Pharmaceuticals made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #1553 holding.
Ladenburg Thalmann Financial Services first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 27 quarters since.
Ladenburg Thalmann Financial Services's Teva Pharmaceuticals position peaked at $2.67M in Q2 2017.
436 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.